XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis

被引：67

作者：

Guo, Yu ^{[1
]}

Xiong, Bing-Hong ^{[2
]}

Zhang, Tao ^{[3
]}

Cheng, Yong ^{[1
]}

Ma, Li ^{[4
]}

机构：

[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 1 Youyi Rd, Chongqing 400016, Peoples R China

[2] Kunming Med Univ, Affiliated Hosp 1, Dept Gastrointestinal & Hernia Surg, Sch Clin Med 1, Kunming, Peoples R China

[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing 400016, Peoples R China

[4] Third Hosp Mianyang, Dept Emergency, Mianyang, Peoples R China

来源：

CANCER INVESTIGATION | 2016年 / 34卷 / 02期

关键词：

Colorectal cancer; Fluorouracil; Capecitabine; Oxaliplatin; CAPECITABINE PLUS OXALIPLATIN; RANDOMIZED PHASE-III; 1ST-LINE TREATMENT; ORAL CAPECITABINE; COLON-CANCER; FLUOROURACIL; LEUCOVORIN; THERAPY; 5-FLUOROURACIL/LEUCOVORIN; SURVIVAL;

D O I：

10.3109/07357907.2015.1104689

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety. Only randomized controlled trials (RCTs) comparing XELOX versus FOLFOX were included. A total of 4,363 patients from eight RCTs were available for analysis. Pooled analysis revealed that there were no statistical differences between both arms in OS, and ORR. XELOX arm had a higher incidence of thrombocytopenia, hand-foot syndrome, and diarrhea, whereas neutropenia had a higher incidence in the FOLFOX group. For mCRC, the effect of XELOX is similar to FOLFOX.

引用

页码：94 / 104

页数：11

共 50 条

[1] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
J Cassidy
S Clarke
E Díaz-Rubio
W Scheithauer
A Figer
R Wong
S Koski
K Rittweger
F Gilberg
L Saltz
[J]. British Journal of Cancer, 2011, 105 : 58 - 64
[2] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
Cassidy, J.
Clarke, S.
Diaz-Rubio, E.
Scheithauer, W.
Figer, A.
Wong, R.
Koski, S.
Rittweger, K.
Gilberg, F.
Saltz, L.
[J]. BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 58 - 64
[3] Cost-analysis of xelox vs. folfox-4 ± bevacizumab (BEV) in metastatic colorectal cancer (MCRC) in an Italian hospital setting
Garrison, L. P.
Giuliani, G.
Ducournau, P.
Cirrincione, A.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A334 - A334
[4] FOLFOX VERSUS FOLFIRI FOR METASTATIC COLORECTAL CANCER: A SYSTEMATIC REVIEW WITH META-ANALYSIS
Sasse, Andre Deeke
Saito, Helena
[J]. ANNALS OF ONCOLOGY, 2011, 22 : v100 - v100
[5] A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Budhi, I. B.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1284 - S1284
[6] Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
Teitelbaum, Ursina R.
Haller, Daniel G.
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (05) : 250 - 251
[7] Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
Ursina R. Teitelbaum
Daniel G. Haller
[J]. Nature Reviews Clinical Oncology, 2009, 6 : 250 - 251
[8] Pharmacoeconomic analysis of XELOX versus FOLFOX for metastatic colorectal cancer first-line treatment in Taiwan
Chen, H. -H.
Chang, C. -S.
Chen, L. -T.
Chen, W. T. -L.
Hsu, T. -C.
Wang, J. -Y.
[J]. ANNALS OF ONCOLOGY, 2015, 26 : 54 - 54
[9] Cost comparison of XELOX vs. FOLFOX4 ± bevacizumab as first-line treatment in patients with metastatic colorectal cancer (MCRC):: US findings
Garrison, L.
Cassidy, J.
Saleh, M.
Lee, F.
Mena, R.
Fuloria, J.
Chang, V
Ervin, R.
Stella, P.
Saltz, L.
[J]. ANNALS OF ONCOLOGY, 2007, 18 : VII74 - VII74
[10] A comparison of medical resource use for xelox vs. folfox4 ± bevacizumab when administered as firstline treatment for patients with metastatic colorectal cancer(MCRC)
Scheithauer, W.
Cassidy, J.
Figer, A.
Wong, R.
Koski, S.
Lichinitser, M.
Yang, T.
Clarke, S.
Diaz-Rubio, E.
Garrison, L.
[J]. ANNALS OF ONCOLOGY, 2007, 18 : VII86 - VII86

← 1 2 3 4 5 →